About us
Scientific Advisory Board
Marien de Jonge
Dr. Marien de Jonge is Associate Professor at Radboud University Medical Center, acting as Head of the Pediatric Infectious Diseases Section. He has more than 15 years of experience in both academic research and industrial R&D, mainly in the field of vaccine development and infectious diseases.
Dr. Harry Flore
Dr. Harry Flore, is Chairman of the Supervisory Board of HAL Allergy Holding of Leiden, the Netherlands - one of Europe’s top players in the field of allergen immunotherapy, and a world leader in the production of modified allergen extracts for both therapeutic and diagnostic purposes. He is also active in HALIX, a CDMO, specializing in cell culture-based pharmaceutical production.
Prof. dr. Anke Huckriede
Prof. Dr. Anke Huckriede is Professor of Vaccinology at the University of Groningen, the Netherlands, and is affiliated with the University Medical Center Groningen. Huckriede’s research activities are aimed at vaccine development, with a focus on rational vaccine design. Her work on (influenza) vaccines focuses, among other things, on developing in vitro techniques for vaccine evaluation and understanding the effects of pre-existing immunity on responses to vaccination.
Dr. Paul Wichgers Schreur
Dr. Paul Wichgers Schreur is a senior scientist in the field of arbovirology at Wageningen Bioveterinary Research (WBVR). Using techniques like reverse-genetics, single-molecule microscopy, and bacterial superglue he studies the infection cycle of bunyaviruses and uses this knowledge to (co)develop therapeutic antibodies and vaccines.
About us
Join our Community
Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.
Subscribe to our news update
Stay up to date with the latest developments, and be the first to receive our news updates and announcements.
